Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025 - CORRECTED

Correction: The Year-End Report referred to in the press release published earlier today was inadvertently omitted. The complete report is now attached.

We have reached important results staying uncompromisingly focused on what matters and refusing to be distracted. By replacing estimation with evidence, we are turning a great invention into a great product.

1 JANUARY – 31 DECEMBER 2025

SIGNIFICANT EVENTS DURING THE QUARTER

22-10-2025 - Spermosens receives patent approval in Canada

03-11-2025 - Spermosens receives patent approval in Mexico

04-11-2025 - Spermosens receives patent approval in Israel

18-11-2025 - Spermosens receives patent approval in China

08-12-2025 - Spermosens announces outcome of exercise of warrants series TO 4

09-12-2025 - Spermosens shares progress and plans for partner-driven commercialization

SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD

16-01-2026 - Spermosens and Sapyen sign Memorandum of Understanding to advance male fertility diagnostic

26-01-2026 - Spermosens and RSI sign Memorandum of Understanding to advance male fertility diagnostics in the US

FINANCIAL INFORMATION

Amounts in SEK thousand	2025 Q4	2024 Q4	2025 Full Year	2024 Full Year
Net sales	–	–	–	–
Operating profit/loss	-2 121	-2 373	-9 201	-9 163
- Whereof activated work for own account	318	408	837	4 120
Cash and cash equivalents	6 836	659	6 836	659
Total Cash flow	-2 236	530	6 177	-3 833
Equity end of period	32 411	27 345	32 411	27 345
Balance sheet total	33 940	31 044	33 940	31 044
Equity/assets ratio,%	95	88	95	88

Liquidity ratio,%	510	47	510	47
No. of shares	3 173 024 065	283 607 120	3 173 024 065	283 607 120
Weighted average number of shares, adjusted for dilution effect	3 173 024 065	283 607 120	2 537 686 452	187 569 007
Earnings per share, SEK	-0,001	-0,01	-0,004	-0,04
Number of employees at end of period	4	3	4	3

CEO STATEMENT

When I joined Spermosens in May 2024, I saw a company with a unique technological foundation and a robust patent portfolio. However, great inventions only become great products when they serve a clear, undeniable purpose. Since then, we have disciplined every effort toward turning that potential into tangible progress. Today, we are not only developing a diagnostic tool; we are addressing a fundamental gap in reproductive healthcare.

Infertility is a global challenge, with male factors contributing to roughly half of all cases. For too long, the industry has relied on limited assessments that leave couples and clinicians uncertain. Our clinical study completed in June was a turning point. The results demonstrated a correlation between JUNO binding, which measures the sperm's functional ability to bind to the egg, and fertilization rates. By providing the only method that measures this critical biological interaction, we move from estimation to evidence. The data strengthen our position as we aim to give clinicians clear guidance and help couples with the answers they need.

Innovation requires protection, and this year we successfully expanded our intellectual property foundation. Our core patent is now granted in key global markets, including Europe, North America, China, Japan and Australia. This creates a secure, long-term framework for our commercialization efforts.

We are making significant progress toward bringing JUNO-*Checked* to major markets. Our goal is to reach clinics, laboratories and patients through innovative companies who combine strong commercial networks with a focus on male infertility and patient-centric care. We are in contact with several companies in the US, Europe and Asia. Our Memoranda of Understanding with Sapyen and RSI Technology Group are important steps forward. While these agreements are indicative, they provide the structure to map our technology into our potential partners' clinical networks. This process is instrumental in aligning our technical requirements with their commercial operations as we move toward formal licensing and partner agreements.

The progress we have made is the work of a small team of extraordinary people. We have reached important results staying uncompromisingly focused on what matters and refusing to be distracted. This strict discipline has enabled us be fast, precise and ready to bring our innovative solution to the market while maintaining a low burn-rate. We have directed our capital away from overhead and into a potential solution in reproductive healthcare.

To fuel our mission, we secured a strategic investment in the first quarter of 2025. The support from investors in Germany, Scandinavia and the United States provides validation of our strategy.

The future of Spermosens lies in our ability to integrate our technology into modern laboratories and clinics. Development of our Generation 3 system is progressing according to plan and is expected to be completed first half of 2026. The system is designed for higher throughput, faster results and ease of use. We are now preparing for technical and clinical validation of the third-generation platform. Our goal is to meet the specifications required for successful commercialization and integration into routine fertility workflows.

Throughout 2025, our strategy has aligned clinical evidence, product development and partnership discussions. What motivates me most is the dedication and focus of our team as we transform scientific milestones into solutions that make a meaningful difference for people who are trying to start families. This year, we are dedicated to the completion and validation of Generation 3 and advancing our partnership frameworks into commercial reality. We are building a company that creates long term value for our shareholders by solving one of the most significant and personal challenges of our time.

Tore Duvold

Tore Duvold, CEO of Spermosens AB